FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration
June 13 2017 - 6:59AM
Business Wire
Leaders in flow cytometry tools collaborate to
deliver cloud data management capabilities and streamline
experimental execution
FlowJo, LLC, a life science informatics and data analysis
company with 20 years of experience in software for analyzing
single-cell data, and global medical technology company, BD
(Becton, Dickinson and Company) (NYSE:BDX), announced today that
they have established a strategic relationship to catalyze the
coordination of resources, people and data for the research
market.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170613005290/en/
Under the agreement, the companies are collaborating to offer
the cloud-based platform, FlowJo Envoy, with BD FACSymphony™, a
cell analyzer enabling the simultaneous measurement of up to 50
different characteristics of a single cell.* The combination will
enable researchers to improve their workflow, collaborations, store
their data in the cloud and share single-cell analysis data in
real-time.
“After speaking with scientific resource laboratory leaders
about their frustrations with coordinating experiments using email
threads and social media, we are excited to bring together the BD
FACSymphony cell analyzer and FlowJo Envoy to enable scientists to
collaborate, coordinate and execute high-parameter single-cell
experiments seamlessly in real-time,” said Michael Stadnisky, Ph.D,
CEO of FlowJo, LLC.
FlowJo Envoy offers a platform enabling researchers to create
and edit a workflow, select instruments for each step, assign steps
to collaborators, and upload data and all associated files.
Everything is searchable and organized according to the projects
and studies the lab is undertaking. In addition, it offers rich
comment features and subscriptions to workflow updates so that
communication about an experiment stays proximal to the details,
SOPs, experimental progress and data.
“Modern application containerization has allowed us to rapidly
bring to market a cloud-based platform that will help accelerate
research and collaborations on high-parameter flow in a scalable
and secure platform,” said Seth Duncan, director of Information
Systems and Technology at FlowJo, LLC.
FlowJo and BD made the announcement at CYTO 2017, the 32nd
Congress of the International Society for Advancement of Cytometry,
being held June 10-14 at the Hynes Convention Center in Boston.
FlowJo Envoy by FlowJo, LLC is available now. For more
information about FlowJo Envoy, to request a free trial license, or
to get up-to-date training on single-cell data analysis, visit
www.flowjo.com.
* The BD FACSymphony system and FlowJo Envoy are intended for
Research Use Only and not for use in diagnostic or therapeutic
procedures.
About FlowJo, LLC
FlowJo, LLC is a privately-owned life sciences informatics
company in Ashland, Oregon. Based on technology developed at
Stanford, the company was founded in 1997 and provides the leading
analysis platform for single-cell flow cytometry analysis. Their
software innovations enable collaboration, discovery,
high-throughput analysis, and data leadership in single-cell
biology. For more information, see www.flowjo.com.
About BD
BD is a global medical technology company that is advancing the
world of health by improving medical discovery, diagnostics and the
delivery of care. BD leads in patient and health care worker safety
and the technologies that enable medical research and clinical
laboratories. The company provides innovative solutions that help
advance medical research and genomics, enhance the diagnosis of
infectious disease and cancer, improve medication management,
promote infection prevention, equip surgical and interventional
procedures, and support the management of diabetes. The company
partners with organizations around the world to address some of the
most challenging global health issues. BD has nearly 50,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170613005290/en/
FlowJo, LLCCaitlin
Farquharcaitlinf@flowjo.comorBDTroy Kirkpatrick,
858-617-2361BD Public Relationstroy.kirkpatrick@bd.comorMonique N.
Dolecki, 201-847-5378BD Investor
RelationsMonique_Dolecki@bd.com
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2023 to Apr 2024